Stopping GLP-1s? Heart benefits vanish fast, study warns

Individuals who discontinue GLP-1 receptor agonists, such as Ozempic and Wegovy, may lose substantial cardiovascular benefits, according to recent findings. These medications, used for weight loss and diabetes management, have demonstrated a notable reduction in heart attack and stroke risks. A study analyzing U.S. veteran data revealed that continuous use over three years led to an 18% decrease in cardiovascular events.

Researchers were particularly struck by the speed at which these protective effects diminished. Stopping the medication for just six months was associated with a 4% increase in cardiovascular risk, escalating to a 22% increase after two years off the drugs. This rapid erosion means that protection accumulated over years can disappear within months.

While restarting GLP-1 medications can partially restore heart health benefits, the recovery is not complete. Uninterrupted use yielded an 18% risk reduction, whereas restarting offered only a 12% reduction, indicating that discontinuation leaves a lasting impact. This phenomenon, described as 'metabolic whiplash,' underscores the critical nature of long-term adherence for sustained cardiovascular health.

The study, primarily involving older male veterans, suggests GLP-1s should be viewed as long-term treatments rather than short-term solutions. Experts emphasize that while these drugs enhance metabolic health, they must be combined with lifestyle modifications like diet and exercise for optimal and lasting outcomes. Patients are advised to consult healthcare providers for comprehensive discussions on the benefits and risks.